Management of atrial fibrillation in patients with heart failure: From drug therapy to ablation

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 3, 2009, Pages 311-322

  Wongcharoen, Wanwarang ^a   Chen, Shi Ann ^b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Anti arrhythmic drug; Atrial fibrillation; Cardiac rynchonization therapy; Catheter ablation; Heart fallure; Rate control; Rhythm control

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; DRONEDARONE; ENALAPRIL; IRBESARTAN; PLACEBO; SOTALOL; VERAPAMIL;

ARTIFICIAL HEART PACEMAKER; CALCIUM CELL LEVEL; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVERSION; CATHETER ABLATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART RATE AND RHYTHM; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; LIVER DISEASE; LUNG DISEASE; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; QT PROLONGATION; REVIEW; SINUS RHYTHM; SKIN DISEASE; THYROID DISEASE; TORSADE DES POINTES; ANIMAL; METHODOLOGY; PROGNOSIS;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; PROGNOSIS;

EID: 66149164741     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.7.3.311     Document Type: Review

References (92)

1. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Ann. Intern. Med. 106(4), 503-506 (1987).
2. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N. Engl. J. Med. 306(17), 1018-1022 (1982).
3. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J. Am. Coll. Cardiol. 32(1), 197-204 (1998).
4. Schotten U, Ausma J, Stellbrink C et al. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation 103(5), 691-698 (2001).
5. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am. J. Cardiol. 69(19), 1570-1573 (1992).
6. Schoonderwoerd BA, Van Gelder IC, van Veldhuisen DJ et al. Electrical remodeling and atrial dilation during atrial tachycardia are influenced by ventricular rate: role of developing tachycardiomyopathy. J. Cardiovasc. Electrophysiol. 12(12), 1404-1410 (2001).
7. Tsang TS, Gersh BJ, Appleton CP et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J. Am. Coll. Cardiol. 40(9), 1636-1644 (2002).
8. Gottdiener JS, Kitzman DW, Aurigemma GP, Arnold AM, Manolio TA. Left atrial volume, geometry, and function in systolic and diastolic heart failure of persons > or =65 years of age (the cardiovascular health study). Am. J. Cardiol. 97(1), 83-89 (2006).
9. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 100(1), 87-95 (1999).
10. Neuberger HR, Schotten U, Blaauw Y et al. Chronic atrial dilation, electrical remodeling, and atrial fibrillation in the goat. J. Am. Coll. Cardiol. 47(3), 644-653 (2006).
11. Sanders P, Morton JB, Davidson NC et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation 108(12), 1461-1468 (2003).
12. Wang TJ, Larson MG, Levy D et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107(23), 2920-2925 (2003).
13. Heist ER, Ruskin JN. Atrial fibrillation and congestive heart failure: risk factors, mechanisms, and treatment. Prog. Cardiovasc. Dis. 48(4), 256-269 (2006).
14. Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc. Res. 60(2), 315-325 (2003).
15. Li D, Melnyk P, Feng J et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 101(22), 2631-2638 (2000).
16. Bode F, Katchman A, Woosley RL, Franz MR. Gadolinium decreases stretch-induced vulnerability to atrial fibrillation. Circulation 101(18), 2200-2205 (2000).
17. + regulatory proteins in the atrial tissue of patients with chronic atrial fibrillation. J. Am. Coll. Cardiol. 34(1), 255-263 (1999).
18. Rosamond W, Flegal K, Friday G et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115(5), e69-e171 (2007).
19. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am. J. Cardiol. 91(6A), 2D-8D (2003).
20. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J. Am. Coll. Cardiol. 32(3), 695-703 (1998).
21. Olsson LG, Swedberg K, Ducharme A et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J. Am. Coll. Cardiol. 47(10), 1997-2004 (2006).
22. Miyasaka Y, Barnes ME, Gersh BJ et al. Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: acommunity-based study over two decades. Eur. Heart J. 27(8), 936-941 (2006).
23. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 347(23), 1825-1833 (2002).
24. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356(9244), 1789-1794 (2000).
25. Carlsson J, Miketic S, Windeler J et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J. Am. Coll. Cardiol. 41(10), 1690-1696 (2003).
26. Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. 347(23), 1834-1840 (2002).
27. Opolski G, Torbicki A, Kosior DA et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 126(2), 476-486 (2004).
28. Hagens VE, Crijns HJ, Van Veldhuisen DJ et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the Rate Control versus Electrical cardioversion (RACE) study. Am. Heart J. 149(6), 1106-1111 (2005).
29. Corley SD, Epstein AE, DiMarco JP et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109(12), 1509-1513 (2004).
30. Roy D, Talajic M, Nattel S et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med. 358(25), 2667-2677 (2008).
31. Khan MN, Jais P, Cummings J et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N. Engl. J. Med. 359(17), 1778-1785 (2008).
32. Torp-Pedersen C, Moller M, Bloch-Thomsen PE et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N. Engl. J. Med. 341(12), 857-865 (1999).
33. Singh SN, Fletcher RD, Fisher SG et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N. Engl. J. Med. 333(2), 77-82 (1995).
34. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114(7), e257-354 (2006).
35. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 98(23), 2574-2579 (1998).
36. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 104(3), 292-296 (2001).
37. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur. Heart J. 24(16), 1481-1487 (2003).
38. Singh BN, Connolly SJ, Crijns HJ et al. Dronedarone, for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med. 357(10), 987-999 (2007).
39. Kober L, Torp-Pedersen C, McMurray JJ et al. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med. 358(25), 2678-2687 (2008).
40. Waldo AL, Camm AJ, deRuyter H et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 348(9019), 7-12 (1996).
41. Lehmann MH, Hardy S, Archibald D, quart B, MacNeil DJ. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 94(10), 2535-2541 (1996).
42. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J. Am. Coll. Cardiol. 20(3), 527-532 (1992).
43. Haissaguerre M, Jais P, Shah DC et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 339(10), 659-666 (1998).
44. Chen SA, Hsieh MH, Tai CT et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 100(18), 1879-1886 (1999).
45. Pappone C, Rosanio S, Augello G et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J. Am. Coll. Cardiol. 42(2), 185-197 (2003).
46. Hsu LF, Jais P, Sanders P et al. Catheter ablation for atrial fibrillation in congestive heart failure. N. Engl. J. Med. 351(23), 2373-2383 (2004).
47. Chen MS, Marrouche NF, Khaykin Y et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J. Am. Coll. Cardiol. 43(6), 1004-1009 (2004).
48. Gentlesk PJ, Sauer WH, Gerstenfeld EP et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J. Cardiovasc. Electrophysiol. 18(1), 9-14 (2007).
49. Tondo C, Mantica M, Russo G et al. Pulmonary vein vestibule ablation for the control of atrial fibrillation in patients with impaired left ventricular function. Pacing Clin. Electrophysiol. 29(9), 962-970 (2006).
50. Cox JL, Jaquiss RD, Schuessler RB, Boineau JP. Modification of the maze procedure for atrial flutter and atrial fibrillation. II. Surgical technique of the maze III procedure. J. Thorac. Cardiovasc. Surg. 110(2), 485-495 (1995).
51. Damiano RJ Jr, Gaynor SL, Bailey M et al. The long-term outcome of patients with coronary disease and atrial fibrillation undergoing the Cox maze procedure. J. Thorac. Cardiovasc. Surg. 126(6), 2016-2021 (2003).
52. Gillinov AM, McCarthy PM. Advances in the surgical treatment of atrial fibrillation. Cardiol. Clin. 22(1), 147-157 (2004).
53. Stulak JM, Dearani JA, Daly RC, Zehr KJ, Sundt TM, 3rd, Schaff HV. Left ventricular dysfunction in atrial fibrillation: restoration of sinus rhythm by the Cox-maze procedure significantly improves systolic function and functional status. Ann. Thorac. Surg. 82(2), 494-500; discussion 500-491 (2006).
54. Nitta T. Surgery for atrial fibrillation. Ann. Thorac. Cardiovasc. Surg. 11(3), 154-158 (2005).
55. Wudel JH, Chaudhuri P, Hiller JJ. Video-assisted epicardial ablation and left atrial appendage exclusion for atrial fibrillation: extended follow-up. Ann. Thorac. Surg. 85(1), 34-38 (2008).
56. Olshansky B, Rosenfeld LF, Warner AL et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J. Am. Coll. Cardiol. 43(7), 1201-1208 (2004).
57. Segal JB, McNamara RL, Miller MR et al. The evidence regarding the drugs used for ventricular rate control. J. Fam. Pract. 49(1), 47-59 (2000).
58. Joglar JA, Acusta AP, Shusterman NH et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am. Heart J. 142(3), 498-501 (2001).
59. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J. Am. Coll. Cardiol. 42(11), 1944-1951 (2003).
60. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 83(1), 52-60 (1991).
61. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N. Engl. J. Med. 336(8), 525-533 (1997).
62. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 9(19), 2388-2442 (2008).
63. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation 101(10), 1138-1144 (2000).
64. Ozcan C, Jahangir A, Friedman PA et al. Significant effects of atrioventricular node ablation and pacemaker implantation on left ventricular function and long-term survival in patients with atrial fibrillation and left ventricular dysfunction. Am. J. Cardiol. 92(1), 33-37 (2003).
65. Williamson BD, Man KC, Daoud E, Niebauer M, Strickberger SA, Morady F. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N. Engl. J. Med. 331(14), 910-917 (1994).
66. Zile MR, Blaustein AS, Shimizu G, Gaasch WH. Right ventricular pacing reduces the rate of left ventricular relaxation and filling. J. Am. Coll. Cardiol. 10(3), 702-709 (1987).
67. Blanc JJ, Etienne Y, Gilard M et al. Evaluation of different ventricular pacing sites in patients with severe heart failure: results of an acute hemodynamic study. Circulation 96(10), 3273-3277 (1997).
68. Brignole M, Gammage M, Puggioni E et al. Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial fibrillation. Eur. Heart J. 26(7), 712-722 (2005).
69. Doshi RN, Daoud EG, Fellows C et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J. Cardiovasc. Electrophysiol. 16(11), 1160-1165 (2005).
70. Patlolla V, Alsheikh-Ali AA, Al-Ahmad AM. The renin - angiotensin system: a therapeutic target in atrial fibrillation. Pacing Clin. Electrophysiol. 29(9), 1006-1012 (2006).
71. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J. Am. Coll. Cardiol. 41(12), 2197-2204 (2003).
72. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc. Res. 54(2), 456-461 (2002).
73. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100(4), 376-380 (1999).
74. Vermes E, Tardif JC, Bourassa MG et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107(23), 2926-2931 (2003).
75. Maggioni AP, Latini R, Carson PE et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am. Heart J. 149(3), 548-557 (2005).
76. Ducharme A, Swedberg K, Pfeffer MA et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am. Heart J. 152(1), 86-92 (2006).
77. Madrid AH, Bueno MG, Rebollo JM et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106(3), 331-336 (2002).
78. Ueng KC, Tsai TP, Yu WC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur. Heart J. 24(23), 2090-2098 (2003).
79. Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J. Am. Coll. Cardiol. 45(11), 1832-1839 (2005).
80. Steinberg JS. Desperately seeking a randomized clinical trial of resynchronization therapy for patients with heart failure and atrial fibrillation. J. Am. Coll. Cardiol. 48(4), 744-746 (2006).
81. Linde C, Leclercq C, Rex S et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the Multisite Stimulation in cardiomyopathy (MUSTIC) study. J. Am. Coll. Cardiol. 40(1), 111-118 (2002).
82. Gasparini M, Auricchio A, Regoli F et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J. Am. Coll. Cardiol. 48(4), 734-743 (2006).
83. Gasparini M, Auricchio A, Metra M et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur. Heart J. 29(13), 1644-1652 (2008).
84. Delnoy PP, Ottervanger JP, Luttikhuis HO et al. Comparison of usefulness of cardiac resynchronization therapy in patients with atrial fibrillation and heart failure versus patients with sinus rhythm and heart failure. Am. J. Cardiol. 99(9), 1252-1257 (2007).
85. Tolosana JM, Hernandez Madrid A, Brugada J et al. Comparison of benefits and mortality in cardiac resynchronization therapy in patients with atrial fibrillation versus patients in sinus rhythm (Results of the Spanish Atrial Fibrillation and Resynchronization [SPARE] Study). Am. J. Cardiol. 102(4), 444-449 (2008).
86. Upadhyay GA, Choudhry NK, Auricchio A, Ruskin J, Singh JP. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J. Am. Coll. Cardiol. 52(15), 1239-1246 (2008).
87. Yu CM, Fang F, Zhang Q et al. Improvement of atrial function and atrial reverse remodeling after cardiac resynchronization therapy for heart failure. J. Am. Coll. Cardiol. 50(8), 778-785 (2007).
88. Hoppe UC, Casares JM, Eiskjaer H et al. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 114(1), 18-25 (2006).
89. Adelstein EC, Saba S. Burden of atrial fibrillation after cardiac resynchronization therapy. Am. J. Cardiol. 100(2), 268-272 (2007).
90. Fung JW, Yip GW, Zhang Q et al. Improvement of left atrial function is associated with lower incidence of atrial fibrillation and mortality after cardiac resynchronization therapy. Heart Rhythm 5(6), 780-786 (2008).
91. Cheng JW. Vernakalant in the management of atrial fibrillation. Ann. Pharmacother. 42(4), 533-542 (2008).
92. Amit G, Qin H, Donahue JK. Biological therapies for atrial fibrillation. J. Cardiovasc. Pharmacol. 52(3), 222-227 (2008).